FLUMIST QUADRIVALENT Rx
Generic Name and Formulations:
Quadrivalent, live attenuated influenza vaccine (virus types A and B); formulation changes annually; susp in intranasal sprayer; contains gelatin, arginine, gentamicin (trace); preservative-free.
Indications for FLUMIST QUADRIVALENT:
Adults and Children:
<2yrs or ≥50yrs: not recommended. Give before start of flu season; each dose is 0.2mL intranasally (as 0.1mL/nostril). 2–8yrs: 1 or 2 doses/season (depends on vaccination history as per annual ACIP recommendation); if 2 doses, give at least 1 month apart. 9–49yrs: 1 dose/season.
Allergy to egg protein, gentamicin, gelatin, or arginine. Life-threatening reaction to previous flu vaccine. Concomitant aspirin in patients 2–17yrs of age (Reye's syndrome).
Use current formulation only. Asthmatics or children <5yrs old with recurrent wheezing: may be at increased risk of wheezing following administration. Guillain-Barre syndrome within 6 weeks of previous flu vaccine. Underlying medical conditions predisposing to flu complications. Immunocompromised. Have epinephrine inj (1:1000) available. Pregnancy (Cat.B). Nursing mothers.
Concomitant vaccines: see full labeling. Do not administer until 48hrs after antiviral therapy cessation. Do not give antivirals within 2 weeks of administration.
Rhinorrhea/nasal congestion, fever, sore throat, decreased appetite, irritability; wheezing.
Single-dose pre-filled nasal spray (0.2mL)—10
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies